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Abstract
Background:  Drug resistance to chemotherapy is often associated with increased malignancy in
neuroblastoma (NB). One explanation for the link between resistance and malignancy might be that
resistance facilitates cancer progression and invasion. To investigate this hypothesis, adhesion,
transendothelial penetration and NCAM (CD56) adhesion receptor expression of drug-resistant versus
drug-sensitive NB tumor cells were evaluated.
Methods: Acquired drug resistance was mimicked by exposing parental UKF-NB-2, UKF-NB-3 or IMR-
32 tumor cells to increasing concentrations of vincristine- (VCR) or doxorubicin (DOX) to establish the
resistant tumor cell sublines UKF-NB-2VCR, UKF-NB-2DOX, UKF-NB-3VCR, UKF-NB-3DOX, IMR-32VCR and
IMR-32DOX. Additionally, the malignant behaviour of UKF-NB-4, which already possessed the intrinsic
multidrug resistance (MDR) phenotype, was analyzed. UKF-NB-4 exposed to VCR or DOX were
designated UKF-NB-4VCR or UKF-NB-4DOX. Combined phase contrast – reflection interference contrast
microscopy was used to separately evaluate NB cell adhesion and penetration. NCAM was analyzed by
flow cytometry, western blot and RT-PCR.
Results: VCR and DOX resistant tumor sublines showed enhanced adhesion and penetration capacity,
compared to their drug naïve controls. Strongest effects were seen with UKF-NB-2VCR, UKF-NB-3VCR and
IMR-32DOX. DOX or VCR treatment also evoked increased invasive behaviour of UKF-NB-4. The process
of accelerated tumor invasion was accompanied by decreased NCAM surface and protein expression, and
down-regulation of NCAM coding mRNA. Transfection of UKF-NB-4VCR cells with NCAM cDNA led to
a significant receptor up-regulation, paralleled by diminished adhesion to an endothelial cell monolayer.
Conclusion: It is concluded that NB cells resistant to anticancer drugs acquire increased invasive capacity
relative to non-resistant parental cells, and that enhanced invasion is caused by strong down-regulation of
NCAM adhesion receptors.
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Background
Multiple-agent chemotherapy is the conventional therapy
for patients with advanced stages of neuroblastoma (NB)
and disseminated NB. However, drug resistance arises in
the majority of stage IV and relapse NB disease, initially
responding to chemotherapy [1]. Classical multidrug
resistance is attributed to the elevated expression of ATP-
dependent drug-efflux pumps such as P-glycoprotein
(Pgp) or multidrug resistance-associated protein (MRP).
Both drug-efflux pumps are thought to decrease cellular
accumulation of anti-cancer drugs and therefore limit the
success of chemotherapy regimens.
However, recent observations suggest that the hypothesis
of drug-efflux driven chemoresistance might not always
hold true. Retrospective analysis of bladder cancer
patients submitted to chemotherapy have revealed no cor-
relation between tumor progression and Pgp modifica-
tion [2]. Overexpression of Pgp and MRP was also not
correlated to chemoresistance and subsequent tumor
recurrence and progression in sarcoma patients [3]. In
particular, the clinical significance of the expression of the
multidrug resistance gene (MDR1) product Pgp in NB is
still a matter of debate. Although frequent expression of
functional Pgp has been found in patients with NB, no
correlation has been seen between Pgp, disease stage and
histopathological grading [4]. Other studies have also
failed to predict the correlation between MDR1 gene
expression and clinical outcome for children with NB
[5,6].
Recently, we developed multi-drug resistant NB in in vitro
models and have demonstrated for the first time that an
increased malignant phenotype in multidrug-resistant
neuroblastoma cells is not mediated by up-regulated func-
tional Pgp [7]. Rather, chemotherapy might have a direct
impact on the biological characteristics of tumors leading
to increased malignancy and metastasis [8]. Based on this,
we hypothesized that chemoresistance itself might accel-
erate tumor progression and invasion.
To investigate the influence of chemotherapy on tumor
invasion, we used an in vitro model of acquired drug
resistance closely resembling progressive NB disease
through long-term treatment of NB cell lines with vincris-
tine- (VCR) or doxorubicin (DOX) to establish VCR and
DOX-resistant tumor cell sublines (NBVCR and NBDOX).
We additionally analyzed NB tumor cells with intrinsic
multidrug resistance (MDR) phenotype (UKF-NB-4) [9].
A transendothelial migration assay allowed the separate
analysis of tumor cells which adhered to an endothelial
cell monolayer and those which transmigrated beneath
the endothelium. Since surface receptors are strongly
involved in tumor invasion and data has indicated that
changes in neural cell adhesion molecule (NCAM, CD56)
expression play an essential part in the progression of NB,
we investigated NCAM expression. This is of particular
interest because the modulation of NCAM is a rate-limit-
ing event in the metastatic dissemination of tumor cells
[10].
The data provide evidence that NB cells resistant to anti-
cancer drugs acquire increased invasive capacity relative to
non-resistant parental cells, and that enhanced invasion is
caused by strong down-regulation of NCAM adhesion
receptors.
Methods
Cell cultures and induction of drug resistance
The human neuroblastoma cell lines UKF-NB-2, UKF-NB-
3 and UKF-NB-4 were established in our laboratory from
bone marrow metastases. IMR-32 was derived from LGC
Promochem, Wesel, Germany. The vincristine- (VCR) and
doxorubicin-resistant (DOX) cell sublines were estab-
lished by exposing parental UKF-NB-2, UKF-NB-3 [8], or
IMR-32 cells to increasing concentrations of the respective
drug. Solutions of VCR (Sigma-Aldrich, Deisenhofen,
Germany) and DOX (Farmitalia, Milan, Italy) were pre-
pared in accordance to the manufacturer's instructions.
The initial VCR and DOX concentrations were 0.2 ng/ml
and 2 ng/ml medium, respectively. The resistant sublines
were grown for more than 6 months in Iscove's modified
Dulbecco's medium (IMDM; Gibco, Karlsruhe, Germany)
supplemented with 10% fetal calf serum (FCS, Gibco) and
10 ng/ml VCR (UKF-NB-2VCR, UKF-NB-3VCR, IMR-32VCR)
or 20 ng/ml DOX (UKF-NB-2DOX, UKF-NB-3DOX, IMR-
32DOX). All doses were in the range of clinical plasma con-
centrations. Multidrug resistant parental UKF-NB-4 cells
were exposed to 50 ng/ml VCR (UKF-NB-4VCR) or 100 ng/
ml DOX (UKF-NB-4DOX). All cells were subcultured at 5-
day intervals.
Human endothelial cells (HUVEC) were isolated from
human umbilical veins and harvested by enzymatic treat-
ment with chymotrypsin. HUVEC were grown in Medium
199 (M199; Biozol, Munich, Germany), supplemented
with 10% FCS, 10% pooled human serum, 20 µg/ml
endothelial cell growth factor (Boehringer, Mannheim,
Germany), 0.1% heparin, 100 ng/ml gentamycin and 20
mM HEPES-buffer (pH 7.4). Subcultures from passages
2–6 with intact morphology and proliferative capacity
were selected for experimental use.
Monolayer invasion assay
Round cover slips were treated with 3-aminopropyl-tri-
ethoxy-silan (2%; Sigma, München, Germany) – acetone
solution for 60 minutes (20°C) to allow firm adhesion of
HUVEC and placed into six-well multiplates (Falcon Pri-
maria; Becton Dickinson, Heidelberg, Germany). HUVEC
subcultures were transferred to prepared multiplates inBMC Cancer 2006, 6:294 http://www.biomedcentral.com/1471-2407/6/294
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complete HUVEC-medium. When confluency was
reached, 0.5 × 106 neuroblastoma cells/well were carefully
added to the HUVEC monolayer for various time periods.
Subsequently, non-adherent neuroblastoma cells were
washed off using warmed (37°C) M199. The remaining
cells were fixed with 1% glutaraldehyde. Bound tumor
cells were counted in five different fields (5 × 0.25 mm2)
using a phase contrast microscope (20 × objective) and
the mean cellular adhesion rate was calculated.
To separately assess neuroblastoma cells which had pene-
trated the HUVEC monolayer, a reflection interference
contrast microscope with a Ploem apparatus was used.
The relevant theoretical evaluation of reflection contrast
microscopy is given by Bereiter-Hahn et al. and Gingell
and Todd [11,12]. The resulting images were visualized
and amplified by a Proxitronic CCD-camera (Proxitronic,
Bensheim, Germany). The number of penetrated neurob-
lastoma cells were then quantified using the image analyz-
ing system ARGUS 20 (Hamamatsu, Hersching,
Germany). To optimize the signal to noise ratio, online
background subtraction and averaging of 8 images was
performed, using the image processing system QUAN-
TIMET Q520 (Cambridge Instruments, Bensheim). Cells
that penetrated the HUVEC monolayer were counted in
five different fields (5 × 0.25 mm2, 20 × objective), and
mean penetration rate was calculated.
Cell proliferation
Proliferative activity of NB cells and HUVEC was esti-
mated by the PicoGreen assay as described elsewhere [13].
Briefly, at several time points after plating the cells in six-
well multiplates, culture medium was removed and cells
were digested with papain (0.125 mg protein/ml) for 20
h at 60°C. Thereafter, the fluorescent dye PicoGreen
(MoBiTec, Goettingen, Germany), which shows high spe-
cificity for dsDNA, was added (1:200 dilution) for 10 min
at 20°C. Fluorescence intensity was determined using a
computer-controlled fluorescence reader (Cytofluor 2300
plate scanner; Millipore, Eschborn, Germany) at λex =
485 nm and λem = 530 nm.
Plasmids and transfection
UKF-NB-4VCR  cells were transfected using the calcium
phosphate co-precipitation method with full-length
cDNA, encoding the human NCAM-140 kDa isoform
inserted in sense of the eukaryotic expression vector pHβ-
Apr-1-neo [14]. Control cells were transfected with the
expression vector alone. 0.5 × 106 NB were seeded in 25
cm2 culture flasks, grown overnight, and transfected with
2  µg of DNA. After culturing for 16 h in complete
medium, cells were washed twice with PBS without Ca2+
and Mg2+  and then incubated with fresh cell culture
medium. Efficiency of NCAM transfection using pHβ-
Apr1-neo was investigated fluorometrically by calcium
phosphate co-precipitation of pHβ-Apr1-neo in combina-
tion with pEGFP-N1 vector (Clontech GmbH, Heidelberg,
Germany) at a ratio of 1:1. pEGFP-N1 encodes a red-
shifted variant of wild-type GFP which has been opti-
mized for brighter fluorescence and higher expression in
mammalian cells. Fluorescence analysis revealed a trans-
fection rate of pHβ-Apr1-neo of 30%. Viability of the cells,
which was controlled by trypan blue dye exclusion or by
quantitative fluorescence analysis of propidium iodide
uptake, was > 90%.
Evaluation of NCAM surface expression
Neuroblastoma cells were disaggregated mechanically,
washed in blocking solution (PBS, 0.5% BSA) and then
incubated for 60 min at 4°C with FITC-conjugated mon-
oclonal antibody anti-CD56 which detects the NCAM
120, 140 and 180 kDa isoform (clone 16.2). NCAM
expression of NB cells was then measured using a FACscan
(Becton Dickinson; FL-1H (log) channel histogram analy-
sis; 1 × 104 cells/scan) and expressed as mean fluorescence
units (MFU). A mouse IgG1-FITC was used as the isotype
control.
To explore NCAM localization, tumor cells were trans-
ferred to round cover slips which were placed in a 24 well
multiplate. Upon reaching confluency, cell cultures were
washed two times with PBS (with Ca2+ and Mg2+) and
then fixed in cold (-20°C) methanol/acetone (60/40 v/v).
Subsequently, cells were washed again with PBS (without
Ca2+ and Mg2+), and afterwards once with blocking buffer
(0.5% BSA in PBS without Ca2+ and Mg2+). After removing
the washing buffer, cells were incubated for 60 min with
FITC-conjugated anti-NCAM monoclonal antibody. To
prevent photobleaching of the fluorescent dye, cover
glasses with stained cells were taken out of the wells and
the residual liquid was removed. The cells were then
embedded in an antifade reagent/mounting medium mix-
ture (ProLong™ Antifade Kit, MoBiTec, Göttingen, Ger-
many) and mounted on slides. The slides were viewed
using a confocal laser scanning microscope (LSM 10;
Zeiss, Jena, Germany) with a plan-neofluar × 100/1.3 oil
immersion objective.
Western blot analysis
Total NCAM content in neuroblastoma cells was evalu-
ated by Western blot analysis: cell lysates were applied to
a 7 % polyacrylamide gel and electrophoresed for 90 min
at 60 V. The protein was then transferred to nitrocellulose
membranes. After blocking, the membranes were incu-
bated overnight with the anti-NCAM-antibody (dilution
1:1000). HRP-conjugated goat-anti-mouse IgG (Upstate
Biotechnology, Lake Placid, NY, USA; dilution 1:5000)
served as the secondary antibody. The membrane was
briefly incubated with ECL detection reagent (ECL™,BMC Cancer 2006, 6:294 http://www.biomedcentral.com/1471-2407/6/294
Page 4 of 13
(page number not for citation purposes)
Amersham) to visualize the proteins and exposed to an x-
ray-film (Hyperfilm™ EC™, Amersham).
Reverse transcription/polymerase chain reaction (RT/PCR)
Total RNA was extracted and purified with Trizol reagent
according to the manufacturer's instructions and treated
with RNase-free DNase. The NCAM primer sequences
were as follows: for NCAM-180 (AccNo AK056258):
5'CGAGGCTGCCTCCGTCAGCACC 3' and 5'CCGGATC-
CATCATGCTTTGCTCTCG 3'; for NCAM-140 (AccNo
U63041): 5'GAACCTGATCAAGCAGGATGACGG 3' and
5'CCGGATCCATCATGCTTTGCTCTCG 3' [15]. Internal
controls for the RT-PCR reaction was performed by run-
ning parallel reaction mixtures with the housekeeping
gene GAPDH: 5'ATCTTCCAGGAGCGAGATCC 3' and
5'ACCACTGACACGTTGGCAGT 3'. RNA (1–10 µg) was
reverse transcribed and the resulting cDNA directly added
to the polymerase chain reaction. Amplification reactions
(20 µl) were performed in the presence of 1/10 (2 µl) of
the cDNA reaction, with an initial incubation step at 94°C
for 1 min. Cycling conditions consisted of denaturation at
94°C for 1 min, annealing at 55°C for 1 min, and exten-
sion at 72°C for 1 min over a total of 30 cycles. The reac-
tion was completed by another incubation step at 72°C
for 10 min. The PCR products were subjected to electro-
phoresis in 2% agarose gel and visualized by ethidium
bromide.
Statistics
All experiments were performed 3–6 times. Statistical sig-
nificance was investigated by the Wilcoxon–Mann-Whit-
ney-U-test. Differences were considered statistically
significant at a p value less than 0.05.
Results
Drug resistance caused elevated tumor cell adhesion and 
transendothelial penetration
Both VCR and DOX resistance was accompanied by ele-
vated tumor cell adhesion to HUVEC. Table 1 indicates
the level of drug resistance and figure 1 shows adhesion
kinetics of control versus VCR or DOX resistant cell lines.
The number of adherent parental tumor cells rapidly
increased and reached a plateau after 60 (UKF-NB-2) or
120 min (UKF-NB-4, IMR-32). UKF-NB-3 adhesion stead-
ily increased up to 240 min. Significantly more UKF-NB-
2VCR and UKF-NB-3VCR cells attached to HUVEC, com-
pared to the drug naïve control cells. Only slight differ-
ences were observed between IMR-32VCR  and IMR-32
controls (not significant at 30 and 60 min). Surprisingly,
adhesion events of UKF-NB-4 possessing the MDR pheno-
type further increased when the parental cells were
exposed to VCR. The same was true when DOX was
applied to UKF-NB-4, although UKF-NB4VCR had a higher
adhesion capacity than UKF-NBDOX.
DOX resistance caused rapid and strong up-regulation of
IMR-32 adhesion. DOX resistance was also accompanied
by elevated adhesion of UKF-NB-2 cells, when compared
to the controls. However, this effect was not as intense as
in UKF-NB-2VCRcells. No significant difference was
observed between adhesion characteristics of UKF-NB-
3DOX and UKF-NB-3 controls.
Tumor cell penetration through HUVEC monolayers was
evaluated on UKF-NB-2 and the multidrug resistant UKF-
NB-4 cells. All resistant cell sublines had significantly
higher number of transmigrated cells compared to the
parental cell lines: +70% after 2 h, +38% after 4 h for UKF-
NB-2VCR, +362% after 2 h, + 430% after 4 h for UKF-NB-
4VCR, +23% after 2 h, +13% after 4 h for UKF-NB-2DOX,
+81% after 2 h, +92% after 4 h for UKF-NB-4DOX cell sub-
lines (figure 2). 4 h transmigration was also evaluated on
IMR-32DOX or IMR-32VCR cells. Both sublines showed sig-
nificantly higher penetration capacity than the parental
controls (IMR-32DOX: +294% mean; IMR-32VCR: +26%
mean).
The PicoGreen assay, which had been carried out as well,
revealed no proliferative activity of tumor cells during the
experiment which might account for enhanced tumor
adhesion and penetration.
NCAM was down-regulated in drug-resistant cell lines
In good accordance to the adhesion pattern, NCAM sur-
face expression was reduced on VCR-resistant cells:
strongly on UKF-NB-2VCR, UKF-NB-3VCR or UKF-NB-4VCR
cells, and slightly on IMR-32VCR cells, compared to the
NCAM level on the parental cell lines.
DOX-resistant cells showed a spectrum of decrease of
NCAM surface receptors: distinct loss in IMR-32DOX cells,
moderate reduction in UKF-NB-2DOX  or UKF-NB-4DOX
Table 1: Level of drug resistance, indicated as IC50-values (ng/
ml)
Cell line IC50-doxorubicin IC50-vincristin
UKF-NB-2 7.4 ± 3.8 0.78 ± 0.23
UKF-NB-2DOX 62 ± 12 22 ± 7
UKF-NB-2VCR 91 ± 18 51 ± 12
UKF-NB-3 8.9 ± 2.0 0.37 ± 0.12
UKF-NB-3DOX 63 ± 11 195 ± 41
UKF-NB-3VCR 91 ± 18 51 ± 12
IMR-32 6.2 ± 3 0.73 ± 0.51
IMR-32DOX 75 ± 14 2.08 ± 0.34
IMR-32VCR 43 ± 11 20 ± 6
UKF-NB-4 214 ± 31 26 ± 8BMC Cancer 2006, 6:294 http://www.biomedcentral.com/1471-2407/6/294
Page 5 of 13
(page number not for citation purposes)
cells, and slight, non-significant decrease on UKF-NB-
3DOX cells. Figure 3 shows the histogram analysis of one
representative experiment.
NCAM localization was analyzed on UKF-NB-4 cells.
Confocal microscopy demonstrated intense and homoge-
nous NCAM accumulation along the cell boundaries of
UKF-NB-4 cells. When UKF-NB-4 cells were exposed to
VCR (UKF-NB-4VCR), NCAM partially disappeared from
the cell surface and the tumor aggregates became smaller
by cell disaggregation (figure 4). As VCR treatment did not
induce proliferation blockade, diminishing the tumor
aggregates was not caused by a reduced cell growth rate.
Western blot experiments were carried out to measure the
intracellular NCAM protein content in drug resistant ver-
sus non-resistant tumor cells. Figure 5 shows reduced
NCAM proteins in UKF-NB-3VCR and UKF-NB-4VCR cells,
compared to the controls, but similar NCAM content in
IMR-32VCR and IMR-32 control cells. Based on DOX resist-
ant cell lines, NCAM proteins were strongly diminished in
IMR-32DOX, and slightly reduced in UKF-NB-4DOX.
Remarkably, NCAM amount was down-modulated simi-
larly in UKF-NB-3DOX and UKF-NB-3VCR, a phenomenon
which was not observed on the cell surface (NCAMcontrol >
NCAMDOX > NCAMVCR; flow cytometry analysis; figure 3).
A further assessment was carrid out to determine whether
NCAM mRNA expression was affected by VCR or DOX.
Concerning VCR resistance, mRNA encoding the 140 kDa
NCAM isoform was down-regulated in the following
order: UKF-NB-2VCR > UKF-NB-4VCR > UKF-NB-3VCR (fig-
Adhesion kinetics of parental control cells (UKF-NB-2, UKF-NB-3, UKF-NB-4, IMR-32) versus vincristine (UKF-NB-2VCR, UKF- NB-3VCR, UKF-NB-4VCR, IMR-32VCR) or doxorubicin resistant subpopulations (UKF-NB-2DOX, UKF-NB-3DOX, UKF-NB-4DOX,  IMR-32DOX) Figure 1
Adhesion kinetics of parental control cells (UKF-NB-2, UKF-NB-3, UKF-NB-4, IMR-32) versus vincristine (UKF-NB-2VCR, UKF-
NB-3VCR, UKF-NB-4VCR, IMR-32VCR) or doxorubicin resistant subpopulations (UKF-NB-2DOX, UKF-NB-3DOX, UKF-NB-4DOX, 
IMR-32DOX). Adhesion capacity is depicted as tumor cell adhesion/mm2 (mean ± SD; n = 6). X-axis indicates the period of co-
culture. *indicates significant difference to the controls.BMC Cancer 2006, 6:294 http://www.biomedcentral.com/1471-2407/6/294
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ure 6). 140 kDa NCAM mRNA was also reduced in IMR-
32DOX  (strongly) and UKF-NB-2DOX  or UKF-NB-4DOX
(moderately). mRNA encoding the 180 kDa isoform was
also detected in all cell lines, bands of which disappeared
in UKF-NB-2VCR, UKF-NB-4VCR, and IMR-32DOX, or were
diminished in UKF-NB-2DOX, UKF-NB-3DOX (as well as in
UKF-NB-3VCR), and UKF-NB-4DOX cells (figure 6).
NCAM transfection reduced NB cell adhesion
The relevance of NCAM for tumor cell binding to HUVEC
was demonstrated by transfection experiments. Transfec-
tion of UKF-NB-4VCR cells with NCAM cDNA reverted the
VCR evoked down-regulating effect on this receptor and
resulted in a two-fold enhancement of NCAM on the cel-
lular membrane. Viability of UKF-NB-4VCR  was not
affected by this procedure. Adhesion of transfected UKF-
NB-4VCR to HUVEC was significantly reduced, compared
to non-transfected cells (figure 7). Transfection of UKF-
NB-4VCR with a control plasmid did not change NCAM
expression and tumor cell adhesion.
Discussion
Intrinsic or acquired resistance to anticancer agents is a
major obstacle to the success of chemotherapy. In the
present work, we compared the invasive properties of
drug sensitive NB with their drug-resistant sublines, as
well as intrinsically resistant NB which were further
treated with VCR or DOX. The selection of the various
tumor sublines mimicked the severe problems arising in
patients during chemotherapy. Based on our model, we
demonstrate that drug resistant cancer cells develop an
increased malignant phenotype, in part due to enhanced
adhesion and transendothelial penetration, accompanied
by a significant down-regulation of the adhesion receptor
NCAM.
Our findings might explain the paradoxical situation that
tumors sometimes become progressively more malignant
during the course of chemotherapeutic treatment. Slot-
man et al. found an increased incidence of hematogenous
metastases with induction chemotherapy for patients with
Penetration kinetics of parental control cells (UKF-NB-2, UKF-NB-4) versus vincristine (UKF-NB-2VCR, UKF-NB-4VCR) or dox- orubicin resistant subpopulations (UKF-NB-2DOX, UKF-NB-4DOX) Figure 2
Penetration kinetics of parental control cells (UKF-NB-2, UKF-NB-4) versus vincristine (UKF-NB-2VCR, UKF-NB-4VCR) or dox-
orubicin resistant subpopulations (UKF-NB-2DOX, UKF-NB-4DOX). To identify transmigrated NB from the cells which had 
bound to HUVEC, a reflection interference contrast microscope with a Ploem apparatus was used (see materials and methods 
for details). X-axis indicates the period of co-culture. *indicates significant difference to the controls.BMC Cancer 2006, 6:294 http://www.biomedcentral.com/1471-2407/6/294
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advanced head-and-neck squamous carcinomas, com-
pared to patients receiving only surgery and radiotherapy.
They also found an increase in metastases at sites other
than the usual pulmonary site [16]. Stefani and coworkers
reported that the use of hydroxyurea in combination with
radiotherapy for the treatment of head and-neck cancer
yielded no benefit in terms of response rate or survival,
but rather increased the incidence of distant metastases
from 8% to 23% [17]. The administration of a single drug
dose may be sufficient to induce spontaneous metastasis
[18].
Two reports have been published recently which under-
line our observations and suggest that drug resistance in
melanoma and carcinoma cells may confer to a more
invasive phenotype [19,20]. Nevertheless, it is still
hypothesized that resistance to cytotoxic agents and inva-
sive potential is associated with the over-expression of Pgp
drug transporters [19,21]. Notably, increased Pgp expres-
sion was found in metastatic NB cells from bone marrow
samples, as compared to non-metastatic NB [22]. Previ-
ous experiments on UKF-NB-2 and UKF-NB-3 cells also
revealed high amounts of functionally active Pgp in both
DOX and VCR resistant sublines. However, expression of
Pgp was 3.5-fold higher in UKF-NB-2DOX when compared
to UKF-NB-2VCR cells, and therefore does not correlate to
the changes seen with respect to cell adhesion and
transendothelial penetration (UKF-NB-2DOX < UKF-NB-
NCAM surface expression on UKF-NB-2, UKF-NB-3, UKF-NB-4, IMR-32 controls and the respective doxorubicin- (DOX) or  vincristine resistant sublines (VCR) Figure 3
NCAM surface expression on UKF-NB-2, UKF-NB-3, UKF-NB-4, IMR-32 controls and the respective doxorubicin- (DOX) or 
vincristine resistant sublines (VCR). An FITC-conjugated monoclonal antibody anti- CD56, clone 16.2, was used to detect the 
NCAM 120, 140 and 180 kDa isoform. A mouse IgG1-FITC served as the isotype control (IgG). The figure shows the histo-
gram analysis of one representative experiment. The complete experimental data set (MFU +/- SD; n = 6) is given above the 
histograms.BMC Cancer 2006, 6:294 http://www.biomedcentral.com/1471-2407/6/294
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2VCR). Furthermore, pharmacological blockage of Pgp in
resistant UKF-NB-2 and UKF-NB-3 cell lines restored
chemosensitivity, but had no effect on colony formation
and cell survival under serum free conditions [7,8].
Therefore, up-regulation of Pgp itself probably does not
play a leading role in increasing NB malignant biology.
However, concomitant deregulation of other pathways
may result in increased metastatic potential, thus leading
to a poorer prognosis of advanced forms of NB disease. In
our cell culture model, modulation of NCAM seems to be
the major parameter responsible for altered cell adhesion
and penetration. This assumption is based on three obser-
vations: 1. Enhanced tumor binding and transmigration
of drug resistant cell populations only occured when
NCAM receptor expression was reduced. 2. NCAM loss
strongly correlated with the elevation of adhesion and
penetration capacity, and 3. Transfection of UKF-NB-4VCR
cells with NCAM cDNA up-regulated the NCAM expres-
sion level and diminished the interaction events between
tumor and endothelial cells. In good accordance to the
present data, we recently demonstrated an inverse correla-
tion between NCAM expression and NB cell adhesion,
assessed on 11 NB cell lines. In particular, transfection
with a cDNA encoding the human NCAM-140 kD isoform
enhanced NCAM expression and diminished initial NB
cell adhesion, treatment with NCAM antisense oligonu-
cleotides reduced NCAM surface level and induced up-
regulation of NB cell adhesion to endothelium [10].
Several studies have demonstrated the important role of
NCAM in tumor migration and metastasis, with an
inverse relationship between migratory potential of the
cells and NCAM expression. In primitive neuroectoder-
mal tumor cells, an increase in NCAM was paralleled by a
significant reduction in cellular motility and adhesion
capacity [23,24]. In a rat model, NCAM-transfected gli-
oma tumor cells became less invasive and destructive than
control cells with a low NCAM expression level [25].
Diminished expression of NCAM was also associated with
Confocal analysis of NCAM distribution Figure 4
Confocal analysis of NCAM distribution. UKF-NB-4 control versus UKF-NB-4VCR tumor cells were grown in standard medium. 
FITC conjugated monoclonal antibody clone 16.2 was used to analyze NCAM. The figure shows distinct NCAM expression at 
the intercellular boundaries on UKF-NB-4 control cells which is reduced in UKF-NB-4VCR. Scale = 10 µM. × 100/1.3 oil immer-
sion objective.BMC Cancer 2006, 6:294 http://www.biomedcentral.com/1471-2407/6/294
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clinically aggressive colon cancers [26-28], and dissemi-
nation of pancreatic beta tumor cells [29,30]. Tezel et al.
suggested that NCAM expression in tubular adenocarci-
noma of the pancreas has a significant impact on overall
patient survival [31]. It is currently assumed that NCAM,
in its function as a homophilic receptor, stabilizes the pri-
mary tumor or tumor cell aggregates, while circulating in
the blood vessels. Reduction of the NCAM expression
level might lead to a reduction in cell-cell binding forces,
and hence to the release of tumors as single cells. The less
NCAM, the more metastatic cells leave the tumor mass,
and the more penetration events can take place [10]. Con-
sequently, NCAM loss observed in DOX and VCR resistant
NB tumor cells allows more cells to transmigrate the
endothelial blood barrier and extravasate into surround-
ing tissue. In line with this, establishment of DOX or VCR
resistant human glioma cells was accompanied by NCAM
reduction and a concomitant down-regulation of adhe-
siveness [32]. Analyses of tumor samples from relapsed
patients have to be carried out to strenghthen the rele-
vance of the in vitro findings.
Recently, it has been documented that the loss of NCAM
function causes the formation of lymph node metastasis
in pancreatic beta cell carcinogenesis via vascular
endothelial growth factor -C and -D-mediated lymphang-
iogenesis [33]. In a previous work, loss of NCAM resulted
in a failure to activate beta1 integrins via fibroblast growth
factor receptor signalling [29]. Both findings implicate
that NCAM, beside its role as an aggregation stabilizer,
may also act in terms of a "metastasis suppressor protein",
controlling proteins and genes that specifically inhibit the
ability of tumor cells from forming metastases [34].
Our hypothesis of drug evoked alterations of NB tumor
cell binding and transvasation also appears to be applica-
ble to tumor cells with intrinsic drug resistance. UKF–NB-
4 cells with a multidrug resistant phenotype retained the
potential to become even more aggressive when treated
with DOX or VCR. From a clinical viewpoint, chemother-
apy of NB might induce adverse effects concerning tumor
biology. In fact, single chemotherapy may amplify the
process of tumor progression if drug-resistant tumor sub-
clones are present in the initial tumor burden.
The finding that extended drug exposure contributes to
distinct modifications of adhesion receptors and invasive
potential of single cancer cells, independent of Pgp over-
expression, may be a signal to re-assess current therapeutic
protocols. In fact, the use of escalating doses of cyclophos-
phamide and prolonging conventional chemotherapy
with the same drugs has failed to improve the metastasis
complete response rate in NB patients [35]. Since initial
pharmacological attempts to inhibit drug efflux and
increase intracellular drug concentrations have not pro-
vided the desired clinical benefit in relapsed or resistant
paediatric cancers [36], the consequences of drug resist-
ance might preferably be treated by agents which reverse
cellular adhesion. In this context, the branched-chain fatty
acid valproate has been demonstrated to inhibit tumor
cell motility and adhesion by up-regulating NCAM
[37,38]. The same is true for the differentiation inducing
compound trichostatin A [39]. A significant increase of
NCAM expression level accompanied by blocking cellular
adhesion has also been observed when neuroblastoma
cells were treated with retinoic acid [40,41]. The introduc-
tion of differentiation inducing drugs may therefore
advance the treatment of relapsed tumors. Currently, sev-
eral studies dealing with this issue are underway.
It is important to note that extended drug exposure
evoked different responses in the in vitro system described
here. Although drug resistance was established in all
tumor sublines, VCR resistance led to increased attach-
ment of UKF-NB-2, UKF-NB-3 or UKF-NB-4 cell lines, but
not of IMR-32, whereas DOX resistance induced marked
elevation of IMR-32 attachment but had no influence on
UKF-NB-3 adhesion. Alterations in the NCAM expression
level followed the same pattern. Therefore, modifications
Western blot analysis of NCAM from the proteins of UKF- NB-3, UKF-NB-4, IMR-32 (Ctrl) versus vincristine (VCR) or  doxorubicin resistant subpopulations (DOX) Figure 5
Western blot analysis of NCAM from the proteins of UKF-
NB-3, UKF-NB-4, IMR-32 (Ctrl) versus vincristine (VCR) or 
doxorubicin resistant subpopulations (DOX). Cell lysates 
were incubated with anti NCAM (clone 16.2) monoclonal 
antibodies, which detect the NCAM 120, 140 and 180 kDa 
isoform. beta-actin served as the internal control. The figure 
shows one representative from three separate experiments.BMC Cancer 2006, 6:294 http://www.biomedcentral.com/1471-2407/6/294
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of the invasive program cannot be expected in every case
where drug resistance in tumor cells develops. VCR or
DOX resistance might convert NCAM triggered cell adhe-
sion in some but not in all tumor subpopulations, or in
some but not in all tumor patients where chemotherapy
has failed. It is still unknown how drug resistant tumor
cells are selected to became "responders", i.e. increase
their invasive activity. However, if our hypothesis holds
true, a critical selection of those "responding" patients
should be carried out who might be predestined for inno-
vative antitumoral, adhesion blocking strategies.
Conclusion
Evidence is presented showing that tumor cells with
acquired resistance to chemotherapeutic drugs have
enhanced invasive potential caused by a strong down-reg-
ulation of NCAM adhesion receptors. However, the data
are limited to DOX and VCR resistant NB cell lines. There-
fore, the hypothetical possibility that treatment with
chemotherapeutic drugs in general may promote cancer
invasion and metastasis needs further investigation. There
is also no doubt that adhesion receptors different from
NCAM may be altered during anti-tumor therapy. This
includes E-cadherin [42,43], as well as CD44 or ICAM-1
[19,44,45]. Presumably, determination of the expression
pattern of a cohort of surface receptors in individual can-
cer cells will allow better prediction of the clinical
response to chemotherapy. Detailed knowledge of recep-
tor driven tumor dissemination may also provide new
ways to overcome drug resistance.
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Adhesion kinetics of UKF-NB-4VCR and of UKF-NB-4VCR transfected with 2 µg of full-length cDNA encoding the human  NCAM-140 kDa isoforms are shown Figure 7
Adhesion kinetics of UKF-NB-4VCR and of UKF-NB-4VCR transfected with 2 µg of full-length cDNA encoding the human 
NCAM-140 kDa isoforms are shown. Control cells were transfected with the expression vector alone. Data on NCAM sur-
face expression, evaluated by flow cytometry, are given in the lower right hand corner. 100% value = 51.4 ± 18.7 MFU. X-axis 
indicates the period of co-culture (mean ± SD, n=3). *indicates significant difference to UKF-NB-4VCR.BMC Cancer 2006, 6:294 http://www.biomedcentral.com/1471-2407/6/294
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